Showing 1 - 7 results of 7 for search 'Joseph S Bednash', query time: 0.03s Refine Results
  1. 1
    Longitudinal transcriptomic analysis reveals persistent enrichment of iron homeostasis and erythrocyte function pathways in severe COVID-19 ARDS

    Longitudinal transcriptomic analysis reveals persistent enrichment of iron homeostasis and erythrocyte function pathways in severe COVID-19 ARDS by Moemen Eltobgy, Finny Johns, Daniela Farkas, Laura Leuenberger, Sarah P. Cohen, Kevin Ho, Sarah Karow, Gabrielle Swoope, Sonal Pannu, Jeffrey C. Horowitz, Rama K. Mallampalli, Joshua A. Englert, Joseph S. Bednash, Joseph S. Bednash

    Published 2024-08-01
    Get full text
    Article
  2. 2
    Corrigendum: Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19

    Corrigendum: Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19 by Bindu Adhikari, Bindu Adhikari, Joseph S. Bednash, Jeffrey C. Horowitz, Mark P. Rubinstein, Mark P. Rubinstein, Anastasia N. Vlasova, Anastasia N. Vlasova

    Published 2024-02-01
    Get full text
    Article
  3. 3
    Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19

    Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19 by Bindu Adhikari, Bindu Adhikari, Joseph S. Bednash, Jeffrey C. Horowitz, Mark P. Rubinstein, Mark P. Rubinstein, Anastasia N. Vlasova, Anastasia N. Vlasova

    Published 2024-02-01
    Get full text
    Article
  4. 4
    SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/2 trial of i.v. citicoline (CDP-choline) in hospitalized SARS CoV-2-infected patients with hypoxemic acute respiratory failure

    SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/... by Sonal Pannu, Matthew C. Exline, Joseph S. Bednash, Joshua A. Englert, Philip Diaz, Amy Bartlett, Guy Brock, Qing Wu, Ian C. Davis, Elliott D. Crouser

    Published 2024-05-01
    Get full text
    Article
  5. 5
    Increased COVID-19 Mortality and Deficient SARS-CoV-2 Immune Response Are Not Associated with Higher Levels of Endemic Coronavirus Antibodies

    Increased COVID-19 Mortality and Deficient SARS-CoV-2 Immune Response Are Not Associated with Higher Levels of Endemic Coronavirus Antibodies by Bindu Adhikari, Eugene M. Oltz, Joseph S. Bednash, Jeffrey C. Horowitz, Joshua O. Amimo, Sergei A. Raev, Soledad Fernández, Mirela Anghelina, Shan-Lu Liu, Mark P. Rubinstein, Daniel M. Jones, Linda J. Saif, Anastasia N. Vlasova

    Published 2023-09-01
    Get full text
    Article
  6. 6
    Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion

    Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion by Pei Li, Yajie Liu, Julia N. Faraone, Cheng Chih Hsu, Michelle Chamblee, Yi-Min Zheng, Claire Carlin, Joseph S. Bednash, Jeffrey C. Horowitz, Rama K. Mallampalli, Linda J. Saif, Eugene M. Oltz, Daniel Jones, Jianrong Li, Richard J. Gumina, Shan-Lu Liu

    Published 2024-05-01
    Get full text
    Article
  7. 7
    Targeted degradation of extracellular mitochondrial aspartyl-tRNA synthetase modulates immune responses

    Targeted degradation of extracellular mitochondrial aspartyl-tRNA synthetase modulates immune responses by Benjamin S. Johnson, Daniela Farkas, Rabab El-Mergawy, Jessica A. Adair, Ajit Elhance, Moemen Eltobgy, Francesca M. Coan, Lexie Chafin, Jessica A. Joseph, Alex Cornwell, Finny J. Johns, Lorena Rosas, Mauricio Rojas, Laszlo Farkas, Joseph S. Bednash, James D. Londino, Prabir Ray, Anuradha Ray, Valerian Kagan, Janet S. Lee, Bill B. Chen, Rama K. Mallampalli

    Published 2024-07-01
    Get full text
    Article

Search Tools: